Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

KEYNOTE-522 updates: Pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 18.12.19
Views: 661
Rating:

Prof Peter Schmid - St Bartholomew's Hospital London, London, UK

Prof Peter Schmid speaks to ecancer at the 2019 San Antonio Breast Cancer Symposium about the recent results from the KEYNOTE-522 study.

This was a study of neoadjuvant pembrolizumab and chemo vs placebo and chemotherapy, followed by adjuvant pembrolizumab vs placebo for early triple-negative breast cancer.

Prof Schmid provides a detailed look at the results and discusses what further analyses might be undertaken.

Watch the press conference here

Read more about the study here

Related videos

follow us

Biosimilar Medicines Core Principles and Communication


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation